Indications |
Oral Contraception Adult: 0.5 mg daily when used alone or 0.75-2.5 mg daily when used in combination with an oestrogen. Oral Menstrual disorders Adult: 5-10 mg daily as cyclic regimen. |
Contraindications |
Undiagnosed vaginal bleeding, active venous thromboembolic disorders or severe arterial disease, hepatic impairment, progestogen-dependent tumours, porphyria. Pregnancy. |
Warnings / Precautions |
CV or renal dysfunction, hypertension, epilepsy, migraine, asthma, DM, conditions which may be exacerbated by fluid retention, malabsorption syndrome, post ectopic pregnancy, functional ovarian cysts, thromboembolism. Lactation. |
Adverse Reactions |
GI disturbances, changes in appetite or weight, fluid retention, oedema, rashes, urticaria, mental depression, breast tenderness and pain, gynaecomastia, changes in libido, headache, migraine, altered menstrual cycle, irregular menstrual bleeding, changes in LFTs and serum lipid profile. Potentially Fatal: Anaphylaxis or anaphylactoid reactions. |
Drug Interactions |
Increased metabolism and subsequent reduction in efficacy with enzyme-inducing agents e.g. carbamazepine, griseofulvin, phenobarbital, phenytoin and rifampicin. Adjustment in antidiabetic dose may be required. Potentially Fatal: May increase plasma levels and toxicity of ciclosporin. See Below for More lynestrenol Drug Interactions |
Mechanism of Actions |
Lynestrenol is a progestogen structurally related to norethisterone. It may be used alone or as the progestogenic component of some oral contraceptives. |
Administration |
May be taken with or without food. |
ATC Classification |
G03AC02 - lynestrenol ; Belongs to the class of progestogens. Used as systemic contraceptives. G03DC03 - lynestrenol ; Belongs to the class of estren derivative progestogens used in progestogenic hormone preparations. |
Available As |
|
Lynestrenol
Post Review about Lynestrenol Click here to cancel reply.
Lynestrenol Containing Brands
Lynestrenol is used in following diseases
Drug - Drug Interactions of Lynestrenol
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.